233 related articles for article (PubMed ID: 21293094)
1. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
Rossi A; Cañas F; Fagiolini A; Larmo I; Levy P; Montes JM; Papageorgiou G; Sturlason R; Zink M; Correll CU
Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094
[TBL] [Abstract][Full Text] [Related]
2. Strategies for successful clinical management of schizophrenia with ziprasidone.
Fagiolini A; Cañas F; Gallhofer B; Larmo I; Levy P; Montes JM; Papageorgiou G; Zink M; Rossi A
Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
[TBL] [Abstract][Full Text] [Related]
3. Focus on ziprasidone.
Green B
Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
[TBL] [Abstract][Full Text] [Related]
4. Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies.
Stip E; Zhornitsky S; Potvin S; Tourjman V
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):997-1000. PubMed ID: 20470848
[TBL] [Abstract][Full Text] [Related]
5. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ortiz-Garcia de la Foz V; Martínez-Garcia O; Valdizan EM; Vazquez-Barquero JL
J Clin Psychopharmacol; 2013 Apr; 33(2):215-20. PubMed ID: 23422371
[TBL] [Abstract][Full Text] [Related]
8. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
[TBL] [Abstract][Full Text] [Related]
9. Ziprasidone as a possible cause of cleft palate in a newborn.
Peitl MV; Petrić D; Peitl V
Psychiatr Danub; 2010 Mar; 22(1):117-9. PubMed ID: 20305605
[TBL] [Abstract][Full Text] [Related]
10. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
11. Ziprasidone: a novel psychotropic with unique properties.
Ballas C; Yang C; O'Reardon J; Ballas P; Baldassano C
Expert Rev Neurother; 2004 Mar; 4(2):179-86. PubMed ID: 15853558
[TBL] [Abstract][Full Text] [Related]
12. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
Kohen I; Preval H; Southard R; Francis A
Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
[TBL] [Abstract][Full Text] [Related]
13. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.
Brook S
J Clin Psychiatry; 2003; 64 Suppl 19():13-8. PubMed ID: 14728085
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
Mencacci C;
Pharmacopsychiatry; 2012 Sep; 45(6):236-40. PubMed ID: 22592506
[TBL] [Abstract][Full Text] [Related]
15. Parkinsonism with intramuscular ziprasidone.
Bilal L; Tsai C; Gasper JJ; Ndlela JC
Am J Psychiatry; 2005 Dec; 162(12):2392-3. PubMed ID: 16330610
[No Abstract] [Full Text] [Related]
16. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():19-25. PubMed ID: 14728086
[TBL] [Abstract][Full Text] [Related]
17. Ziprasidone-associated pedal edema in the treatment of schizophrenia.
Ku HL; Su TP; Chou YH
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):963-4. PubMed ID: 16624468
[TBL] [Abstract][Full Text] [Related]
18. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone.
Scahill L; Blair J; Leckman JF; Martin A
J Psychopharmacol; 2005 Mar; 19(2):205-6. PubMed ID: 15728441
[No Abstract] [Full Text] [Related]
19. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
[No Abstract] [Full Text] [Related]
20. Ziprasidone and cognition: the evolving story.
Harvey PD
J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]